bioAffinity Technologies (BIAF) Equity Ratio (2021 - 2026)

bioAffinity Technologies has disclosed Equity Ratio across 6 years of filings, most recently posting 0.46 for Q1 2026.

• In Q1 2026, Equity Ratio rose 77.6% year-over-year to 0.46; the TTM figure through Mar 2026 stood at 0.46 (up 77.6% YoY), while the FY2025 annual figure was 0.66, up 66.21% from the prior year.
• Equity Ratio slipped to 0.46 in Q1 2026, from 0.66 in the prior quarter.
• Over the last five years, Equity Ratio for BIAF reached as high as 0.92 in Q1 2023 and fell as low as 0.45 in Q2 2025.
• The 5-year median for Equity Ratio is 0.65 (2024), against an average of 0.58.
• Annual changes were most pronounced in 2022 — Equity Ratio soared 108.34% — and 2025, when it sank 187.17%.
• A 5-year view of Equity Ratio shows it stood at 0.91 in 2022, then slumped by 34.86% to 0.59 in 2023, then sank by 32.36% to 0.4 in 2024, then jumped by 66.21% to 0.66 in 2025, then tumbled by 30.6% to 0.46 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.46, 0.66, and 0.77 for Q1 2026, Q4 2025, and Q3 2025 respectively.